#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dementia Alzheimer's type Dermatitis atopic Asthma Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Urea cycle disorder Autoimmune demyelinating disease Burkitt's lymphoma Immunodeficiency common variable Necrotising enterocolitis neonatal Type IIa hyperlipidaemia Cholangiocarcinoma Primary hyperoxaluria Anti-glomerular basement membrane disease Hypertriglyceridaemia Thrombocytosis HER2 gene amplification Precursor T-lymphoblastic lymphoma/leukaemia recurrent Monogenic diabetes Duchenne muscular dystrophy gene carrier More trials…

    Learn about Rare Diseases

    Noonan syndrome – Life with Disease Wolfram syndrome Antithrombin III deficiency – Life with Disease Cytokine release syndrome – Treatment Biotinidase deficiency Propionic acidaemia MELAS syndrome – Trials in Disease Kearns-Sayre syndrome – Diagnostics Hepatoblastoma – Life with Disease Extranodal marginal zone B-cell lymphoma (MALT type) – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Fluticasone Propionate Clofazimine Mva-209-Fsp-B1 Ipn01194 Quinidine Sulfate GSKVX000000034792 Inupadenant Hydrochloride Gallium (68Ga) Psma-R2 Placebo Caffeine Citrate Sulodexide Pralsetinib 177LU-FAP-2286 Tofogliflozin Dog Epithelium Extract Cetirizine Apitegromab Simoctocog Alfa Cdr132L Befiradol (18F) More therapies…

    Learn about Your Condition

    Febrile neutropenia Asplenia Chondroplasty Spina bifida Fabry's disease Stress Skin bacterial infection Adenovirus infection Biliary tract disorder Thermal burn Pelizaeus-Merzbacher disease Ovarian cancer stage III Vulvovaginal candidiasis Labour pain Habitual abortion More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Uncategorized

  • Study on Clebopride for Treating Rumination Syndrome in Patients Suspected of Having the Condition

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Merycism
    Investigated Drugs:
    • Clebopride Hydrogen Maleate
    Belgium

  • Study of AZD7798 compared to placebo in patients with moderate to severe Crohn’s disease

    Not recruiting

    2 1
    Investigated Drugs:
    • Azd7798
    Austria Belgium Bulgaria Croatia France Germany +8

  • Study of ODM-208 (opevesostat) safety and effectiveness in patients with metastatic castration-resistant prostate cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Hormone-refractory prostate cancer
    Investigated Drugs:
    • Dobutamine Hydrochloride
    • Odm-208
    • Opevesostat
    Finland France

  • Study of Pacritinib for Patients with Severe Thrombocytopenia in Myelofibrosis Conditions

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Myelofibrosis
    • Primary myelofibrosis
    Investigated Drugs:
    • Betamethasone Sodium Phosphate
    • Danazol
    • Hydroxycarbamide
    Bulgaria Czechia France Hungary Italy Poland +2

  • Study on Birtamimab and Bortezomib for Patients with Advanced Light Chain Amyloidosis

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Primary amyloidosis
    Investigated Drugs:
    • Birtamimab
    • Bortezomib
    • Sodium Chloride
    Austria Belgium Czechia Denmark France Germany +8

  • Study on Ibrutinib and Drug Combination for Patients with Generalized Mantle Cell Lymphoma

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Mantle cell lymphoma stage II
    • Mantle cell lymphoma stage III
    • Mantle cell lymphoma stage IV
    Investigated Drugs:
    • Ibrutinib
    Belgium Czechia Denmark Finland Germany Italy +6
Previous Page
1 … 1,675 1,676 1,677 1,678 1,679 … 1,695
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!